Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of once-daily oral semaglutide in adults with overweight or obesity
2025-524626-18-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in Overweight and obesity comparing Oral semaglutide (Rybelsus) with Placebo (2 arms). Primary endpoint: Relative change in body weight. Planned start Aug 2026; status: authorised.
02
Drugs
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on 2025-524626-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524626-18-00.